{"entity":{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","aka":[],"tldr":"Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.","summary":"Bradley Monk (GOG Partners) was a lead investigator of GOG 240, which established bevacizumab in advanced cervical cancer, and co-led KEYNOTE-826, innovaTV 301 (tisotumab vedotin) and KEYNOTE-A18, together the three practice-changing cervical cancer trials of the past five years. He co-leads the GOG Partners industry-collaboration programme and has led ovarian PARP inhibitor trials including ATHENA.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Bradley_J._Monk","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monk%20BJ%5BAuthor%5D%20cervical"}],"tags":["cervical","ovarian","cooperative-group"],"related":[],"cancers":["cervical","ovarian"],"sections":[],"technologies":["checkpoint-inhibitor","adc"],"targets":["pd1","tissue-factor","vegf"],"drugs":["pembrolizumab","tisotumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-826","innovatv-301","keynote-a18","athena-mono"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners","specialisms":["Cervical cancer","Ovarian cancer","Antibody-drug conjugates","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monk%20BJ%5BAuthor%5D%20cervical"}],"papers":[{"title":"Improved survival with bevacizumab in advanced cervical cancer (GOG 240)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1309748"},{"title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2112435"}]},"route":"/people/bradley-monk/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"}],"trial":[{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/"},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/"},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/"},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/"},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/"}]}}